Updated 11 August 2026
When will GLP-1 tablets be available in the UK?
The answer changed in 2026. The first GLP-1 weight-loss tablet is already here in the UK, but not every oral medicine people search for is at the same stage. The only reliable way to read this topic is medicine by medicine.
Short answer
The first UK weight-loss GLP-1 tablet is already available
The Wegovy pill, which is oral semaglutide for weight management, was approved by the MHRA on 11 June 2026 and is now listed by UK private providers. Other oral medicines, including orforglipron, remain future-watch stories rather than live UK access routes.
Available in the UK now
Wegovy pill: available through private providers. The 1.5mg and 4mg strengths are live now; 9mg and 25mg are due from 20 July 2026. This is the first GLP-1 receptor agonist tablet licensed in the UK for weight management.
Rybelsus: available, but for type 2 diabetes. It belongs in the oral semaglutide conversation, but it is not the same as saying the UK has multiple weight-loss GLP-1 tablets already on sale.
Not yet available in the UK
Orforglipron, brand name Foundayo: not yet available in the UK. It was approved in the United States on 1 April 2026, but US approval does not create UK access on its own. It still needs UK licensing and then, separately, any future NHS commissioning route.
That matters because “approved somewhere” and “buyable in Britain” are not the same thing. At the moment, Foundayo should be treated as a tracked future medicine, not a current UK provider option.
Why US approval does not mean UK availability
A medicine can generate headlines long before it becomes a real UK option. The sequence is different:
- US approval only covers the United States.
- UK supply requires MHRA authorisation for the UK market.
- NHS access, if it comes later, depends on NICE and local commissioning rather than the approval headline alone.
That is why a US story can be useful context but still leave UK readers with nothing they can actually order.
What counts as “available” on this site
Provider wording can make this topic noisier than it needs to be. “Notify me”, “join the waitlist”, “coming soon” and “pre-order” do not mean the same thing as an active UK supply route.
On Tablet Compare, a medicine only counts as available when the UK licence, the provider route and the live public offer all line up clearly enough to stand on their own. That is why the Wegovy pill has moved into the live category, while Foundayo has not.
What about non-GLP-1 weight-loss tablets?
If the real question is “which weight-loss tablets can I get in the UK?”, the answer is broader than GLP-1 medicines alone.
- Orlistat is already available and works by reducing fat absorption.
- Mysimba is already licensed in the UK as a private weight-loss option, but it is not a GLP-1 medicine.
Those sit in different treatment categories, but they matter because many UK searches use “GLP-1 tablets” when the real need is simply a legitimate tablet route for weight management.
How to check a provider claim before you trust it
- Check whether the exact medicine has a UK licence for the use being discussed.
- Treat waitlists and notify-me pages as interest signals, not current access.
- Make sure the provider is a genuine UK pharmacy route with a real clinical assessment process.
- Separate weight-loss claims from diabetes-only products such as Rybelsus.
Read the provider-claim checklist if you want the practical version of that process.
Common questions
GLP-1 tablets UK FAQ
Can you get GLP-1 tablets in the UK yet?
Yes. The Wegovy pill is now available in the UK through private providers, and Rybelsus has an existing UK diabetes role.
When will Foundayo be available in the UK?
There is no confirmed UK launch date yet. Foundayo was authorised by the MHRA on 10 August 2026. It is a prescription-only medicine and is not funded by the NHS, and no UK provider was dispensing it when we checked on 11 August 2026.
Is the Wegovy pill available on the NHS?
At launch the live route is private. NHS access follows a separate process and should not be assumed from private availability alone.
Does US approval mean a medicine is available in the UK?
No. A medicine still needs UK licensing and any later NHS pathway before it becomes a real UK access route.
Follow the live routes, not the hype
Use the pages below if you want to separate current UK access from future-watch coverage without mixing them together.